COMBINATION targeted therapy significantly slows tumor progression in adult patients with pretreated advanced renal cell carcinoma. In the global phase 3 LITESPARK-011 trial, investigators evaluated the oral hypoxia-inducible factor 2 alpha inhibitor belzutifan in combination with the multi-kinase inhibitor lenvatinib against standard cabozantinib monotherapy. The study enrolled 747 individuals with unresectable, locally advanced or metastatic stage IV clear-cell disease whose malignancy progressed following anti-PD-1 or anti-PD-L1 immune checkpoint inhibition.
Patients assigned to belzutifan plus lenvatinib achieved a median progression-free survival of 14.8 months compared to 10.7 months for cabozantinib monotherapy, representing a significant 30% reduction in the risk of disease progression or death (hazard ratio 0.70; 95% confidence interval 0.59 to 0.84; p < 0.0001). Masked independent central review revealed an objective response rate of 53% in the combination group, including a 5% complete response rate, compared to a 40% overall response rate and a 1% complete response rate with cabozantinib. Furthermore, responses proved remarkably durable, demonstrating a median response duration of 23.0 months versus 12.3 months with standard monotherapy. At the second interim analysis, median overall survival reached 34.9 months with the dual regimen versus 27.6 months with cabozantinib (hazard ratio 0.85; p = 0.061), with long-term survival assessments continuing to the final study evaluation.
Treatment-emergent adverse events of grade 3 or worse occurred at similar frequencies between arms, affecting 84% of combination recipients and 83% of cabozantinib recipients. Hypertension was the most common severe event across both cohorts, noted in 31% and 29% of participants, respectively. Class-specific toxicities required proactive clinical vigilance; anemia occurred in 69% of patients receiving belzutifan plus lenvatinib, while hypoxia emerged in 15%, necessitating supportive management with blood transfusions, erythropoiesis-stimulating agents, or supplemental oxygen therapy. Additionally, cardiac dysfunction arose in 7% of combination participants compared to 1% on cabozantinib. Patient-reported outcomes indicated no substantial disparity between cohorts regarding the time to confirmed worsening in disease-related symptoms or global quality of life. These robust results indicate that dual pathway inhibition provides an effective new treatment paradigm for advanced renal cell carcinoma following immunotherapy failure.
Reference
Motzer RJ et al. Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial. Lancet. 2026;408:808–20.
Featured Image: 9nong on Adobe Stock.
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
